Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation  by Tran, Hai et al.
P
A
A
A
I
n
d
(
a
r
r
[
Biology of Blood and Marrow Transplantation 10:805-812 (2004)
 2004 American Society for Blood and Marrow Transplantation
1083-8791/04/1011-0008$30.00/0
doi:10.1016/j.bbmt.2004.07.010
Bharmacokinetics and Individualized Dose
djustment of Intravenous Busulfan in Children with
dvanced Hematologic Malignancies Undergoing
llogeneic Stem Cell Transplantation
Hai Tran,1,2 Demetrios Petropoulos,3 Laura Worth,3 Craig A. Mullen,3 Timothy Madden,2
Borje Andersson,1 Mary Choroszy,3 John Nguyen,2 Susannah K. Webb,2 Ka Wah Chan3
1Divisions of Cancer Medicine, 2Pharmacy, and 3Pediatrics, The University of Texas M.D. Anderson Cancer
Center, Houston, Texas
Correspondence and reprint requests: Hai T. Tran, PharmD, Divisions of Cancer Medicine and Pharmacy, The
University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 432, Houston, TX 77030 (e-mail:
htran@mdanderson.org).
Received December 12, 2003; accepted July 27, 2004
ABSTRACT
We investigated the pharmacokinetics (PK) of a recently approved intravenous busulfan (IVBU) formulation as
a part of the preparative regimen in 20 children with advanced hematologic malignancies undergoing alloge-
neic hematopoietic stem cell transplantation. Seventeen patients received a thiotepa, IVBU, and cyclophos-
phamide–based regimen, and 3 patients received an IVBU and cyclophosphamide–based regimen. All patients
received IVBU 0.8 mg/kg for the first 2 doses; thereafter, the IVBU dose was modified, if required, to achieve
a final area under the concentration-time curve (AUC) at steady state of 1150 mol/L/min per dose (range,
1000-1300 mol/L/min per dose; SD 13%) based on the first-dose PK determination. PK studies were
repeated on subsequent doses to verify the final AUC. Initial mean IVBU clearance and half-life were 3.96
mL/min/kg and 1.98 hours, respectively. Sixteen (80%) of the 20 patients received dose adjustments: 14
patients required dose escalations, and 2 required dose reductions. Overall, thirteen (72%) of 18 available
sample sets at final follow-up PK analysis showed the IVBU exposure to be within the targeted range. IVBU
PK was linear, and interpatient variability was much lower than that observed with oral busulfan. IVBU was
well tolerated, and no case of hepatic veno-occlusive disease was encountered. Mild and transient hyperbil-
irubinemia was observed in 7 patients. Thirteen of the 20 patients were alive at a median follow-up of 651 days
(range, 386-1555 days). We conclude that a standardized IVBU dose of 0.8 mg/kg in children does not always
result in an AUC within the reference range defined in this study. Therapeutic drug monitoring with dose
adjustment based on first-dose PK can optimize the systemic busulfan exposure for children undergoing
allogeneic hematopoietic stem cell transplantation.
© 2004 American Society for Blood and Marrow Transplantation
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High-dose busulfan (BU) is an important compo-
ent of many myeloablative regimens for patients un-
ergoing hematopoietic stem cell transplantation
HSCT). Steady-state BU plasma concentrations and
reas under the concentration-time curve (AUC) cor-
elate with the incidence of graft failure, transplant-
elated mortality, and relapse of the primary disease
1-3]. Until recently, BU was available only in the oral d
B&MTormulation. When oral BU is used in a high-dose
reparative regimen before transplantation in chil-
ren, a number of unfavorable proﬁles have been
escribed. These include delayed and variable absorp-
ive characteristics, high variability in drug metabo-
ism, and more rapid, age-dependent clearance of the
rug [4-6]. Children up to 6 years of age have a
igniﬁcantly higher clearance of oral BU. Although
osing BU according to body-surface area approxi-
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8ates its clearance to that observed in adults, this
pproach does not correct interpatient differences in
learance. Additionally, the high emetogenic potential
f BU, which requires empirical replacement of vom-
ted tablets, also adds to the complexity of optimizing
ystemic drug exposure. Therapeutic drug monitoring
TDM) of oral BU with dosage adjustment is widely
racticed, with variable results [6-8].
Advantages of administering BU intravenously
IV) include assurance of 100% bioavailability, avoid-
nce of the ﬁrst-pass effect, ease of administration, and
ssurance that the prescribed dose has been received.
t may reduce the large variability in drug disposition
hile ensuring adequate systemic drug exposure. IV
dministration is particularly useful in children who
ave difﬁculty swallowing a large number of tablets
or myeloablative regimens.
A parenteral formulation of BU (IVBU; Busulfex
njection; ESP Pharma, Edison, NJ) was approved in
999 for clinical use in adults at a dose of 0.8 mg/kg in
ombination with cyclophosphamide as a preparative
egimen for HSCT. Results from the phase I and II
tudies in adults showed that this new formulation was
ell tolerated and provided a more consistent phar-
acokinetic (PK) proﬁle and dosing reliability than
hat reported with oral BU [9,10].
Data on the use of IVBU in children are very
imited. We previously reported a feasibility study of
ndividualizing oral BU dosing on the basis of ﬁrst-
ose PK [6]. We showed that this approach could
aximize the therapeutic effects of BU while mini-
izing toxicities. However, variable drug absorption
nd excessive vomiting remained signiﬁcant problems
ith oral BU. In this study, we substituted IVBU for
ts oral formulation in transplant conditioning regi-
ens for children with advanced hematologic malig-
ancies. We also determined the PK parameters of
VBU and the usefulness of dose adjustment in the
ediatric age group.
ATIENTS AND METHODS
atients
Children and young adults 21 years of age with
ecurrent or high-risk leukemia or lymphoma were
ligible. Patients also met the following criteria: left
entricular ejection fraction 50%, serum creatinine
nd bilirubin levels no more than twice the upper limit
f normal for age, serum alanine aminotransferase
evel no more than 3 times the upper limit of normal,
uman immunodeﬁciency virus antibody negative,
nd Lansky performance status 70%. Patients who
eceived a transplant during the ﬁrst or second com-
lete remission of acute leukemia from an HLA-iden-
ical donor (related or unrelated) were considered
tandard risk; the rest of the patients were regarded as i
06igh risk. The transplantation protocols were ap-
roved by the Institutional Review Board of The Uni-
ersity of Texas M.D. Anderson Cancer Center, and
ritten informed consent was obtained from parents
r guardians for all patients.
reatment Plan
Two IVBU-based treatment regimens were used.
eventeen patients were treated on the thiotepa, BU,
nd cyclophosphamide regimen, which consisted of
hiotepa (250 mg/m2 IV over 4 hours daily on days
9, 8, and 7), BU (initial dose of 0.8 mg/kg IV
very 6 hours for 2 doses; the remaining 10 doses were
hen dosed on the basis of ﬁrst-dose AUC determina-
ion, on days6,5, and4), and cyclophosphamide
60 mg/kg IV over 2 hours on days3 and2). Three
atients were treated on the IVBU and cyclophos-
hamide regimen. This consisted of IVBU 0.8 mg/kg
very 6 hours for 2 doses, and the remaining 14 doses
ere dosed on the basis of ﬁrst-dose AUC determi-
ation, on days 7 to 4, followed by cyclophos-
hamide 60 mg/kg IV on days3 and2. Because all
patients underwent unrelated donor transplanta-
ions, they also received antithymocyte globulin
0 mg/kg IV on days 3, 2, and 1. IVBU was
iluted in normal saline to a concentration of 0.5
g/mL and was infused through a central venous
atheter during 2 hours. A standard amount of IVBU,
.7 mg (3.08 mL of drug solution), was added to the
alculated dose to ﬁll the priming volume of the IV
ubing. Doses of IVBU were calculated by using the
ctual body weight to the nearest one hundredth of a
illigram. Subsequent dosage was adjusted, as
eeded, to reach a targeted BU AUC of 1150 mol/
/min per dose (range, 1000-1300 mol/L/min per
ose; SD 13%) at steady state. The reference range
f 1000 to 1300 mol/L/min per dose was based on
he median of the AUC range (1500 mol/L/min per
ose) achieved by Andersson et al. [10] in adults, with
variance of 15%.
To prevent seizures, all patients received loraz-
pam, which was administered from 24 hours before
he ﬁrst IVBU dose to 24 hours after the last IVBU
ose. Lorazepam rather than phenytoin was given for
eizure prophylaxis because a number of adverse
vents have been associated with the use of phenytoin
n this setting, and it may interfere with BU metabo-
ism [11]. Mesna 10 mg/kg IV every 4 hours was used
or uroprotection during and for 24 hours after cyclo-
hosphamide administration. Bone marrow, blood
tem cells, or umbilical cord blood from related or
nrelated donors was infused for hematopoietic re-
onstitution on day 0. No T-cell depletion was per-
ormed. Patients were monitored and received sup-
ortive care according to standard procedures in our
nstitution. Filgrastim at a dose of 5 to 10 g/kg/d was
g
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Pharmacokinetics of IV Busulfan in Children
Biven subcutaneously from day 1 until engraftment.
acrolimus, along with methotrexate, was given for
he prevention of acute graft-versus-host disease
GVHD), as previously described [12].
tudy Evaluation
The modiﬁed National Cancer Institute common
oxicity criteria (version 2.0) were used to score pul-
onary, cardiac, hepatic, renal, gastrointestinal, blad-
er, and neurologic complications until day 28. The
ones criteria were used for the diagnosis of hepatic
eno-occlusive disease (VOD) [13]. Engraftment was
ssessed by peripheral blood count recovery and mar-
ow examination and was conﬁrmed by conventional
estriction fragment length polymorphism and cyto-
enetic analysis [14]. To document disease response,
one marrow aspiration was performed at 1, 3, 12, and
4 months after HSCT and additionally at any time
hen clinically indicated.
All patients were followed up through March 31,
004, with a minimum follow-up of 13 months after
ransplantation. Actuarial estimates of treatment-re-
ated mortality and survival were calculated according
o the method of Kaplan and Meier [15]. Conﬁdence
ntervals were calculated with True Epistat statistical
oftware (Epistat Services, Houston, TX). Median val-
es were compared by using the Mann-Whitney U
est [16], and the Wilcoxon signed rank test [17] was
sed to compare matched samples. All P values were 2
ailed, and P  .05 was considered signiﬁcant.
K Studies
Heparinized blood samples (2-3 mL) were
rawn in conjunction with the administration of
oses 1, 5, 9, and 13 (if applicable) of IVBU imme-
iately before drug infusion and 0.5, 1, 2, 4, 5, and
hours after the start of infusion (n  7 samples).
ecause IVBU was administered through a central
enous catheter, all blood samples for PK studies
ere collected from a peripheral IV catheter to
void contamination caused by the proximity be-
ween the lumens of the catheter used for infusion.
amples were separated via centrifugation at 1500
pm for 15 minutes in a refrigerated centrifuge at
°C. For doses 1 and 5, plasma samples were ana-
yzed immediately on the same day. Samples from
oses 9 and 13 were cryopreserved at 70°C until
nalysis at a later time. Samples were subjected to
rocessing and separation with high-pressure liquid
hromatography, as previously described [6,9,18].
arameters such as the volume of distribution of the
entral compartment and the elimination rate con-
tant were estimated, and the steady-state volume of
istribution, half-life, and clearance were calculated
rom the primary parameters. The AUC per IVBU 3
B&MTose was calculated by using the following formulas,
s previously described [6]:
nitial AUC(mol/L/min) [dose(mg/kg/dose) ⁄
clearance(L/min/kg)] 4.065
ew dose(mg/kg/dose) [target AUC (mol/L/
min/dose) clearance(L ⁄min ⁄ kg)] 0.246
ose adjustments were made at the third dose,
f necessary, to target an AUC at steady state of
150 mol/L/min per dose (range, 1000-1300 mol/
/min per dose). The maximum limit of IVBU dosage
hange was set at 50%, and the clinical status of the
atient was also taken into account as to where in the
herapeutic range the target with the dose adjustment
ould be.
PK modeling was performed with ADAPT II
oftware, version 4.0 (BMRS, University of Southern
alifornia, Los Angeles, CA). A 1-compartment open
odel with a weighted least squares regression model
as used to evaluate individual patient sets of concen-
ration-time data [19]. The ﬁfth and ﬁnal IVBU AUC
as calculated by using the PK parameters determined
y modeling the IVBU plasma concentration versus
ime data of all the doses tested from each patient’s
ata set. These 2 subsequent PK estimates were used
o predict the performance of the model of ﬁrst-dose
ata. No IVBU dose adjustments were made from
hese revised (ﬁfth and ﬁnal) parameter estimates de-
ived from multiple-dose data.
ESULTS
atient Characteristics
Between May 1999 and January 2003, a total of 20
atients met the eligibility criteria and were treated on
he adjusted-dose protocols. Their clinical character-
stics are described in Table 1. Median age was 5.5
ears (range, 0.8-14.9 years). Median weight of the
atients was 22.3 kg (range, 8.7-56.4 kg). Eleven pa-
ients were in the high-risk group, and 7 of these
atients had active disease at the time of pretransplan-
ation conditioning. Sixteen patients received HSCTs
rom unrelated donors, and 4 patients, from HLA-
dentical siblings. For the unrelated-donor group, 2
ransplantations were performed with HLA-matched
arrow donors, and 14 transplantations were per-
ormed with umbilical cord blood units mismatched at
(n  1), 1 (n  5), 2 (n  6), or 3 (n  2) HLA loci.
U PK and Dose Adjustments
Table 2 summarizes the results of the PK analysis.
ll patients received the ﬁrst 2 doses of IVBU at 0.8
g/kg. The median ﬁrst-dose IVBU clearance was
.94 mL/min/kg (mean, 3.96 mL/min/kg; range, 2.25-
807
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8.47 mL/min/kg). The median initial volume of dis-
ribution was 1.00 L/kg (mean, 1.50 L/kg; range, 0.21-
.83 L/kg), and the median half-life was 1.75 hours
mean, 1.98 hours; range, 1.20-3.64 hours). The me-
ian ﬁrst-dose AUC was 851.5 mol/L/min (mean,
88.5 mol/L/min; range, 436-1437 mol/L/min) for
he entire group. On the basis of the ﬁrst-dose PK
nalysis, 14 patients required dose escalation by 13%
o 50% (median, 34%). Two patients required BU
ose reduction by 8% and 21% to achieve the targeted
ange. Only 4 patients did not require dosage adjust-
ent. The median ﬁnal IVBU dose for the entire
roup was 1.04 mg/kg (mean, 0.99 mg/kg; range,
.63-1.20 mg/kg).
Eighteen of 20 patient sample sets were available
or ﬁnal analysis and PK modeling. These analyses
ombined PK data available from doses 1, 5, and 9
and dose 13 in 2 patients) and demonstrated that 72%
13 of 18) of patients achieved an AUC within the
argeted exposure range of 1000 to 1300 mol/L/min
er dose for a course of therapy. When divided ac-
ording to age (Figure 1), the ﬁnal IVBU clearance
alues were higher in children younger than 6 years
n  9; mean, 4.49 mL/min/kg; SD, 0.69 mL/min/kg)
han for patients 6 years and older (n  9; mean, 3.35
L/min/kg; SD, 0.67 mL/min/kg; P  .0027 by the
tudent t test).
egimen-Related Toxicities
Ten (50%) of 20 patients experienced grade 2 or 3
egimen-related toxicities. Stomatitis, esophagitis, and
iarrhea were the most frequent adverse effects. Nausea
nd vomiting were very mild. Mild intertriginous skin
yperpigmentation and moist desquamation occurred in
third of the patients as a result of thiotepa toxicity.
here were no cases of neurotoxicity. Seven (35%) pa-
able 1. Patient Characteristics
Characteristic
Median (range) or
No. Patients
ge (y) 5.5 (0.8-14.9)
ex (M/F) 12/8
iagnosis
ALL 7
AML 11
MDS 1
JMML 1
isk category
Standard risk 9
High risk 11
tem cell source
Marrow 5
Blood stem cells 1
Cord blood 14
LL indicates acute lymphoblastic leukemia; AML, acute myelog-
enous leukemia; MDS, myelodysplastic syndrome; JMML, ju-
venile myelomonocytic leukemia.ients developed hyperbilirubinemia (grade 1, n  5; s
08rade 2, n  2), but none had other features of hepatic
OD. These complications resolved without treatment
ithin 7 days.
ngraftment, Relapse, and Survival
In this group of 20 patients with advanced hema-
ologic malignancies, all patients survived beyond day
30. Two patients did not show signs of hematologic
ecovery: 1 patient had persistent leukemia, and the
ther patient experienced primary graft failure after a
ismatched unrelated donor umbilical cord blood
ransplantation. All remaining patients recovered with
bsolute neutrophil counts exceeding 500/L. Five of
he 7 patients with active disease at the time of trans-
lantation had achieved complete hematologic remis-
ion on the day 30 bone marrow evaluation. One
atient had marrow aplasia, and another patient had
ersistent leukemia. As of March 31, 2004, a total of
3 patients were alive (median follow-up of the sur-
iving patients, 651 days; range, 386 to 1555 days).
welve (7 of 11 high-risk and 5 of 9 standard-risk)
atients remain in continuous complete remission.
ne patient is alive with recurrent juvenile my-
lomonocytic leukemia. Seven patients have died: 1
eath resulted from GVHD and 6 deaths from recur-
ent leukemia.
ISCUSSION
The therapeutic window of BU in the HSCT pre-
arative regimen is relatively narrow. Leukemia recur-
ence and graft failure have both been associated with
ow BU exposure [1-3]. Andersson et al. [1] reported that
eviation from their therapeutic window of a per-dose
UC between 950 and 1520mol/L/min was associated
ith more disease relapse, more transplantation-related
ortality, more acute GVHD, and a higher day 100
ortality in adult patients with chronic myeloid leuke-
ia. Oral administration of BU is associated with erratic
bsorption, resulting in unpredictable dosing bioavail-
bility and, thus, unpredictable systemic drug exposure.
In children, age-dependent metabolism of BU fur-
her complicates the challenge of optimizing systemic
rug exposure. The blood concentration and clear-
nce might vary up to 6-fold among pediatric patients
eceiving oral BU [4-6]. Because of their higher clear-
nce children require a higher dose of oral BU than
dults to achieve similar exposure. TDM of oral BU
as been considered an essential practice in pediatric
atients undergoing HSCT. We previously showed
hat systemic BU exposure could be projected from
he initial-dose AUC [6]. Individualized oral BU dos-
ng reduced regimen-related toxicities while maximiz-
ng the desired drug effect. However, the inherent
ssue of unpredictable drug absorption cannot be re-
olved.
Table 2. Summary of IVBU PK in Children
Patient
No. Sex Age (y) Weight (kg) Initial Vc (L/kg)
First-Dose
t1/2 (h)
First-Dose
IVBU
Clearance
(mL/min/kg)*
First-Dose
IVBU AUC
(mmol/L/min)† % Change in Dose
New IVBU
Dose (mg/kg)‡
Final IVBU
Clearance
(mL/min/kg)
Final IVBU AUC
(mmol/L/min)†
1 M 12.5 47.8 0.25 2.70 2.25 1437 21 0.63 2.45 1041
2 M 3.5 15.7 1.00 1.40 3.77 826 50 1.15 4.25 1098
3 M 1.0 9.7 3.12 2.12 3.58 936 25 1.03 N/A N/A
4 F 6.0 24.6 0.70 1.64 4.17 781 31 1.05 3.32 1281
5 M 1.7 12.7 2.51 1.72 4.89 665 48 1.18 3.83 1256
6 M 2.2 11.5 2.99 2.50 3.88 839 0 0.80 4.28 910
7 F 4.4 22.0 1.09 1.68 3.55 965 0 0.84 3.39 1007
8 F 2.4 15.2 1.52 1.75 5.56 587 49 1.20 4.89 996
9 M 13.6 38.4 0.42 1.92 4.06 864 30 1.04 3.79 1187
10 M 3.0 13.7 2.83 2.94 4.01 818 42 1.14 4.73 1129
11 F 9.6 31.2 0.72 3.64 2.56 1274 8 0.74 3.91 768
12 F 0.8 9.2 5.83 1.52 7.47 436 49 1.20 5.70 858
13 F 11.0 38.4 0.29 1.75 2.84 1146 0 0.80 2.69 1210
14 M 14.9 54.7 0.21 1.84 3.33 973 13 0.91 2.90 1123
15 M 11.5 31.1 0.39 1.33 4.25 880 31 1.06 3.94 1105
16 F 11.5 33.8 0.35 1.20 2.55 1275 0 0.80 2.79 1016
17 M 8.5 22.5 0.99 1.75 3.61 687 50 1.20 N/A N/A
18 M 13.0 47.4 0.58 1.50 4.92 652 37 1.10 4.34 1190
19 F 5.0 13.7 2.83 2.94 4.01 915 18 0.95 5.04 929
20 M 3.5 16.5 1.29 1.78 3.99 813 31 1.05 4.26 1158
Mean  SD 6.99  4.80 25.5  14.1 1.50  1.44 1.98  0.64 3.96  1.17 909  258 23.72  22.15 0.99  0.17 3.92  0.88 1070  141
Median
(range) 5.5 (0.8-14.9) 22.3 (9.2-54.7) 1.00 (0.21-5.83) 1.75 (1.20-3.64) 3.94 (2.25-7.47) 872 (436-1437) 30.49 (21.1 to 50) 1.04 (0.63-1.2) 3.92 (2.45-5.70) 1102 (768-1281)
Vc indicates volume of distribution; t1/2, half-life; N/A, not available.
*Denotes the normalized clearance of IVBU.
†Area under the concentration-time curve for each dose.
‡Dose change was made from the third administered dose onward.
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8Data from phase I and II studies of IVBU in adults
ave shown that the use of an IV preparation can
nsure more standardized delivery of BU [9,10]. In
hose studies, IVBU was associated with signiﬁcantly
ore consistent drug clearance, AUC, and half-life at
teady state than has been seen with orally adminis-
ered BU. Not only were there small interpatient
ariations in PK, but the IV formulation was also well
olerated. However, similar data on IVBU in children
re lacking.
In this study, we sequentially determined the PK
arameters of IVBU in 20 children undergoing
SCT. The optimal dose for pediatric patients has
ot been determined. Data from the pivotal study of
VBU in adults established that a dose of 0.8 mg/kg of
djusted body weight, infused over 2 hours, yielded
K parameters similar to those observed after an oral
ose of 1 mg/kg body weight [9]. This approved
VBU dosing scheme was adopted as a starting point
or this study. As in adult patients, the PK proﬁle of
his formulation is linear and highly reproducible.
ge-dependent variability in metabolism is also seen
n children receiving IVBU. In this population, the
ifference in drug clearance was up to 3-fold. A higher
VBU clearance rate in children up to 6 years of age
as observed—a ﬁnding that recalled our previous
xperience with oral BU [6].
We observed that two thirds of the patient popu-
ation had an initial AUC projected to be less than the
eference range. Similarly, Wall et al. [20] reported
hat IVBU clearance was higher in young children. To
each the targeted IVBU exposure, these investigators
ecommended an increase in the initial IVBU dose
rom 0.8 mg/kg to 1 mg/kg in children 4 years and
ounger. Using this approach to initial dosing, Grim-
ey et al. [21] reported that a targeted AUC was
IV
BU
 C
le
ar
an
ce
 (m
l/m
in
/k
g)
0
2
4
6
8
igure 1. IBVU clearance by age group. Comparison of ﬁnal clear-
nce between the 2 age groups of individuals younger than 6 years
n  9; mean, 4.49 mL/min/kg; SD, 0.69 mL/min/kg) and those
years or older (n 9; mean, 3.35 mL/min/kg; SD, 0.67 mL/min/kg).
tudent t test; P  .0026; df  16.chieved in 50% of pediatric transplant recipients. In t
10series of 6 children with a median age of 6 years,
remers et al. [22] also found a relatively low AUC
fter an initial dose of 0.8 mg/kg, and the dosage of all
atients was increased to 1 mg/kg. Conversely, Dalle
t al. [23] reported that infants younger than 1 year
ad lower IVBU clearance, and half of the 14 patients
equired IVBU dose reduction.
Recently, the manufacturer of IVBU (ESP Pharma)
rovided the following dosing recommendation based
n the patient’s body weight: patients weighing 12 kg or
ess should receive 1.1 mg/kg per dose, and those over
his weight should be given 0.8 mg/kg per dose. If we
ompare our data with this guideline, then the 3 children
eighing 12 kg or less received a ﬁnal IVBU dose of 0.8,
.03, and 1.2 mg/kg. The median IVBU dose of the 17
eavier children was 1.05 mg/kg, and 13 of these chil-
ren would have been underdosed according to the ref-
rence AUC range in this study.
Caution should be exercised in analyzing the
VBU PK data in this report and others. In addition to
he different dosages used, investigators have not used
uniformly accepted AUC reference range or unit of
easurement. In our study, the AUC reference range
as 1000 to 1300 mol/L/min per dose; others have
xpanded the therapeutic window to between 900 and
500 mol/L/min per dose [7,8,24]. This is an impor-
ant factor to consider when analyzing the frequency
f adjustment based on an individual patient’s AUC.
urthermore, IVBU dosing in all the pediatric studies
eported to date has been on a milligram-per-kilo-
ram basis, and the PK data should be interpreted
ccordingly. Conversely, the PK proﬁle of oral BU in
hildren dosed on a milligram-per-square-meter basis
ore closely approximates the proﬁle seen in adults
3,4,6]. This dosing approach has not yet been tested
n children. Furthermore, because the PK proﬁle of
VBU is highly consistent and reproducible over a
ange of dosing frequencies, IVBU has already been
iven on a daily basis in adults and children. These
arly data showed that the PK proﬁle is linear when
he total BU dose is administered in this manner
25-27].
IVBU was well tolerated in studies of adult trans-
lant recipients. Compared with an oral BU-based
reparative regimen, the incidence of hepatic VOD
as lower and 100-day survival was higher [10,28].
imilarly, we observed minimal toxicity in children
reated with IVBU. No neurotoxicity or hepatic VOD
as observed. Mildly and transiently increased biliru-
in levels were encountered in one third of the pa-
ients—an incidence similar to that reported in adults
26]. The incidence of nausea and vomiting was much
ower than that observed in a previous group of chil-
ren treated with oral BU on the same regimen (data
ot shown). This ﬁnding suggests that vomiting is
ainly due to the difﬁculty of taking a large number ofablets or capsules during a short period. The engraft-
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Bent rate in this study was similar to that reported
hen oral BU was used in the same regimens. In our
atients, IVBU did not demonstrate an adverse effect
n hematologic reconstitution in HSCT, even though
ost patients received stem cells from unrelated do-
ors. Considering the advanced stage of disease in the
atients in this series, the disease-free survival rate is
imilar to that reported in other studies [6,29].
In this study, modest intrapatient variability in
rug clearance was observed, and the PK determina-
ion of the ﬁrst IVBU dose correlated well with that of
he subsequent steady state in 72% of the patients
valuated. Given the more linear and highly reproduc-
ble absorption of this formulation, TDM of IVBU
hould be easier to perform. Using a more limited
ampling schedule (doses 2 through 5) may be ade-
uate to predict AUC. Alternatively, it is also possible
o administer a test dose of IVBU before transplant
onditioning to determine the optimal dose for the
ndividual patient, an approach taken with oral BU
7,24]. It seems that regardless of how IVBU is dosed
n children, maintaining a desired systemic exposure
ill continue to play an important role when using
his agent in HSCT regimens [30].
We conclude that IVBU may be safely used in
lace of oral BU in children. The application of TDM
o the new IV formulation allows for much more
recision in the targeting of systemic BU exposure for
ndividual pediatric patients on the basis of disease
tatus, organ function, and donor source.
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